Recent studies from this laboratory have demonstrated that angiotensin II (Ang II) stimulates the expression of plasminogen activator inhibitor 1 (PAI-1) in cultured endothelial cells. This response does not appear to be mediated via an interaction with either the AT1 or the AT2 receptor subtype. Since a novel angiotensin receptor has been identified in a variety of tissues that specifically binds the hexapeptide Ang IV (Ang II, [3-8]), we therefore examined the effects of Ang IV on the expression of PAI-1 mRNA in bovine aortic endothelial cells. Ang IV stimulated dose-and time-dependent increases in the expression of PAI-1 mRNA. The effect of Ang IV (10 nM) was not inhibited by Dup 753 (1.0 microM), a highly specific antagonist of the AT1 receptor, or by PD123177 (1.0 microM), a highly specific antagonist of the AT2 receptor. In contrast, the AT4 receptor antagonist, WSU1291 (1.0 microM), effectively prevented PAI-1 expression. Although larger forms of angiotensin (i.e., Ang I, Ang II, and Ang III) are capable of inducing PAI-1 expression, this property is lost in the presence of converting enzyme or aminopeptidase inhibitors. These results indicate that the hexapeptide Ang IV is the form of angiotensin that stimulates endothelial expression of PAI-1. This effect appears to be mediated via the stimulation of an endothelial receptor that is specific for Ang IV.
Introduction
The fibrinolytic system serves as one of the major endogenous defense mechanisms against intravascular thrombosis. Endothelial cells play a critical role in the regulation of intravascular fibrinolytic activity, serving as a major source of tissue-type plasminogen activator and its inhibitor, plasminogen activator inhibitor-I (PAI-1 ) in blood. PAI-I is a member of the serine protease inhibitor (serpin) family and was initially identified in the medium of cultured bovine aortic endothelial cells (BAEC) (1) . Endothelial cell production of PAI-I is regulated by a number of factors including TGF-/3, lipopolysaccharide and TNFa (2) , and thrombin (3, 4) .
Before PAI-I was discovered, it was recognized that the prolonged infusion of angiotensin (Ang) IT could precipitate myocardial infarction in animals (5) . The mechanism of this effect has not been characterized, but presumably involves a combination of vasoconstriction and prothrombotic effects (6) . A role for Ang TI in the regulation of fibrinolytic balance was first recognized by Olson et al. (7) who described the induction of PAI-i production by Ang H in cultivated murine astrocytes. This observation has been followed by studies demonstrating that infusion of Ang H to healthy volunteers results in a dosedependent increase in plasma PAI-1 concentrations (8) . Fur- thermore, pharmacological interruption of Ang TI production by an angiotensin converting enzyme inhibitor (ACEI) in patients with uncomplicated myocardial infarction is associated with a reduction in PAI-i activity (9) . Recent studies have confirmed this relationship with Ang H inducing PAI-i expression in vascular smooth muscle cells (10) and in cultured endothelial cells (11) .
Importantly, the induction of PAI-1 expression in BAEC endothelial cells is not prevented by the administration of specific antagonists of either the type 1 or type 2 angiotensin receptor (AT, or AT2, respectively). These results suggest that this response is mediated by a pharmacologically distinct form of the angiotensin receptor. In addition to the AT1 and AT2 receptors, evidence is accumulating supporting the existence of an angiotensin receptor that binds to a smaller fragment of angiotensin, the hexapeptide 3-8 fragment (Ang IV) of Ang IT. Ang IV is generated by the sequential cleavage of two amino acid residues from the amino terminus of Ang H by aminopeptidases localized to the endothelial surface. Binding sites for Ang IV have been recognized in guinea pig brain (12, 13) , mouse neuroblastoma (14) , bovine adrenal cortical cells, and coronary endothelium (15, 16) .
These experiments were designed to characterize further the response of endothelial cells to angiotensin and to address the hypothesis that these responses are mediated by an endothelial receptor that is specific for Ang IV.
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Results
Effect ofAng H on PAI-I mRNA expression. After pretreatment with captopril (10 IM), BAEC were exposed to Ang II (10 nM) for 6 h in the absence and presence of specific antagonists of the AT1 and AT2 receptor subtypes (Dup 753 [1 ,uM] and PD123177 [1 ,uM] , respectively). At the end of the exposure period the cells were washed and solubilized and total RNA was extracted as described. Fig. 1 demonstrates the results of Northern blot analysis using a riboprobe to PAI-i. In control cells, PAI-I mRNA was expressed at low, but detectable, levels. Exposure of the cells to Ang II resulted in a 3.2+1.7-fold (mean±+SEM) increase in the expression of PAI-I message (n = 5). In comparison with cells treated with Ang II alone, the expression of PAI-1 mRNA was 89.6±17.6% (n = 4) in the presence of a 100-fold excess of Dup 753, and 111% (n = 2) in the presence of a 100-fold excess of PD123177. Effect ofAng IVon PAI-I mRNA expression. In these experiments confluent cultures of BAEC were exposed to Ang IV over the concentration range of 0-10 nM (Fig. 2) . Ang IV resulted in a dose-dependent increase in the expression of PAI-1. Compared with vehicle-treated controls, Ang IV (10 nM) induced on average a 5.3±2.6-fold increase in PAI-I mRNA levels (n = 4). A time-dependent effect of Ang IV on PAI-I expression was also demonstrated (Fig. 3 A) . The induction of PAI-I mRNA expression produced by Ang II is evident within 1 h and is maximal at 4 h (Fig. 3 B) .
Effect IV. Amastatin is a potent inhibitor of endopeptidases (20) and prevents the conversion of Ang II to smaller fragments including Ang IV. To investigate the role these aminopeptidases play in regulating the induction of PAI-I mRNA levels by Ang II, cells were exposed to Ang II (10 nM) in the presence of increasing concentrations of amastatin (0-1,000 nM). As demonstrated in Fig. 4 A, amastatin resulted in a dose-dependent reduction in the expression of PAM-i mRNA. In contrast, amastatin did not alter the expression of PAM-i after exposure of the cells to Ang IV (10 nM, Fig. 4 B) . In the presence of amastatin (1 ,4M), the PAI-mRNA signal was 80% of that seen in untreated control cells. In contrast, the PAI-I mRNA expression in cells treated with Ang IV and amastatin (1 MM) was 3.6-fold greater than controls.
[ANGD] (IOnM) [Amastatin] (nM) Fig. 4 B, amastatin had no effect on the response of endothelial cells to Ang IV.
Discussion
These experiments demonstrate that Ang IV induces an increase in the expression of PAI-1 in cultured BAEC. This response exhibits both a time and a dose dependence and it appears that angiotensin is not capable of inducing endothelial PAI-I mRNA expression until it is converted to the hexapeptide Ang IV. These results provide an extension of our prior observations demonstrating the interaction of angiotensin with endothelial cells and suggest that this interaction occurs via the AT4 receptor. This is the first demonstration that the expression of PAI-1 in response to angiotensin exposure is specifically due to Ang IV. Binding sites for a novel angiotensin receptor that is specific for Ang IV have been demonstrated in a variety of tissues including rabbit brain (21) , smooth muscle cells (22) , and mammalian heart membranes (23). In addition, binding sites on endothelial cells have been demonstrated for Ang IV (15) . Functional consequences of the binding of Ang IV include dilatation of rabbit brain arterioles (21) and exploratory locomotor activity in rats (24) .
In this study, we present data demonstrating that the hexapeptide Ang IV is fully capable of inducing endothelial PAI-i expression. Furthermore, this effect can be blocked by a specific AT4 receptor antagonist (WSU1291). Importantly, this effect of the AT4 receptor antagonist appears to be specific and not due to undefined general effects on cellular function, since endothelial cells retain their morphologic characteristics and proliferative capacity when cultured in the presence of WSU1291 (data not shown). All of the experimental data presented in this manuscript were obtained using BAEC that had been subcultured only once. Although later passage cells have been examined for their responses to Ang II and Ang IV, the results have been less consistent. The reasons for this are unclear but may represent a functional manifestation of cellular transformation.
Although prior studies from this laboratory have demonstrated that Ang II stimulates the expression of PAI-1, the specific pharmacological subtype of angiotensin receptor mediating this response was not defined (II). The current studies again demonstrate that angiotensin is capable of stimulating the expression of PAI-i. There were differences in the basal expression of PAI-I expression from experiment to experiment; however, an increase in PAI-I expression in response to Ang II was consistently detected (Figs. 1, 4 A, and 6 (25) . The current studies suggest that the endothelial cell functions autonomously in the conversion of Ang I to Ang IV and confirm a physiologically relevant role for the aminopeptidases. They also support a potentially important role for an aminopeptidase inhibitor in modulating the angiotensin-dependent effects on PAI-1 expression. The response of a structurally distinct aminopeptidase inhibitor, bestatin, has been assessed recently using porcine aortic endothelial cells. Bestatin (1 /uM) results in a similar blunting in the response to Ang II, while this inhibitor does not appear to diminish the response to Ang IV (data not shown).
These results may have important clinical implications. Administration of ACEIs to patients with left ventricular dysfunction is associated with a reduction in the frequency of ischemic events (26) (27) (28) . More recently, Wright et al. (9) demonstrated that the administration of captopril to survivors of uncomplicated myocardial infarctions was associated with a reduction in PAI-1 activity (9). Conversely, infusion of angiotensin results in an acute increase in plasma PAI-1 concentrations (8) . Thus, alterations in the renin-angiotensin system result in alterations in PAI-1, a risk factor for myocardial infarction (29) . In contrast to the beneficial effects of an ACEI on PAI-1 levels, therapeutic administration of specific receptor antagonists to either the AT1 or AT2 receptor subtype would not be expected to reduce endothelial expression of PAI-I and thus may lack this potentially favorable interaction with the fibrinolytic system. Furthermore, AT1 receptor blockers are associated with increased plasma levels of plasma renin activity and Ang 11 (30, 31) , which may lead to increased Ang IV production. This latter effect, if confirmed, could have a deleterious effect on fibrinolytic balance and may inadvertently increase the risk of thrombosis. This later possibility deserves careful scrutiny.
